4 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
Follow TAK-279: new trials by email Literature Review of TAK-279 trials Research Report on TAK-279
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis Zasocitinib - Palmoplantar Psoriasis | Phase 3 | Not yet recruiting | Takeda | 40 | 2026-11-01 | 2026-10-20 |
| A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Zasocitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Takeda | 110 | 2025-12-04 | 2026-09-09 |
| A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis Zasocitinib, Deucravacitinib, Placebo to match zasocitinib - Plaque Psoriasis | Phase 3 | Completed | Takeda | 606 | 2025-07-09 | 2026-05-01 |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis TAK-279 - Plaque Psoriasis | Phase 3 | Active not recruiting | Takeda | 2099 | 2024-09-04 | 2026-06-02 |
| A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis TAK-279 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Completed | Takeda | 18 | 2024-03-19 | 2026-07-30 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 693 | 2023-11-06 | 2025-10-24 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 1108 | 2023-11-06 | 2025-11-20 |
Psoriasis (2) · Arthritis, Psoriatic (1)
Takeda (8)
Japan (5) · Poland (5) · United States (5) · Canada (4) · China (4) · Germany (4) · Bulgaria (3) · Czechia (3) · France (3) · Italy (3) · Latvia (3) · Spain (3) · Argentina (2) · Australia (2) · Hungary (2)
2023 (2), 2025 (1)